Search results for " supply"
Article
Advances in Sterilization Technologies for Overcoming Viral-Vector Manufacturing Challenges
Sterility must be assured for all biologic drug products. Terminal sterilization achieved via treatment with heat, radiation, or certain chemicals (vaporous hydrogen peroxide, vaporous peracet…
Article
Right the First Time: Bioreactor Scale and Design Translation
Cell culture processes need to operate in a design space where the oxygen supply and carbon dioxide removal can match cellular metabolism. In addition, prohibitive high shear stress and high gas flow …
Article
Developing oligonucleotide therapeutics with confidence
In this video, we will look at key considerations for oligo therapeutic developers entering the market, such as scalability, flexibility, regulatory concerns, insource/outsource consideratio…
Article
Process Development and Control for New Modalities
Increasing molecular diversity leads to more challenges in process development and control. Advancements in technology for manufacturing and online analytical monitoring have not caught up…
Article
Modern plasmid purification process
AcuraBio selects Cytiva's latest two-step purification protocol to offer a productive plasmid DNA service to its customers globally to alleviate supply constraints for mRNA and cell & gene th…
Article
What Makes a High-Quality Chromatography Resin?
Learn the process of what makes a high-quality chromatography resin.
WATCH VIDEO >>
Article
Evolving demands of process development services
The final trend that is being seen and, in some ways is linked to the challenges of the pandemic, is the requirement of a partner who can ensure supply chain stability with a robust continuity busines…
Article
Pandemic Alters Policies and Practices for Drug Development and Regulation
FDA used its expanded authority to respond quickly to shortage situations to prevent gaps in the medical product supply chain for multiple vital medicines.
At the same time, curbs on FDA ins…
Article
Cytiva and Pall Corporation Investing 1.5 Billion USD Over Two Years to Meet Growing Demand for Biotechnology Solutions
Click here to read more >>
An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and services acros…
Article
HyClone Characterized FBS – Origin Equivalence Study
FBS from a single origin may be limited, so qualifying FBS from other origins is one way to enhance security of supply. With that in mind, we evaluated HyClone-brand characterized FBS from the United …